P140 Update; Fundraise, Related Party Transaction

AI SummaryClose X

ImmuPharma PLC announced a fundraise of up to £7.5 million at 6.0 pence per share, comprising a £6 million subscription from Lanstead Capital Investors L.P. and a retail offer. The proceeds will accelerate the development of Kapiglucagon for Type 1 diabetes, utilizing the FDA's 505(b)(2) pathway, and are expected to provide a cash runway to at least H2 2028. The company also confirmed its P140 program remains on track for a licensing deal in 2026. The Lanstead subscription includes a sharing agreement where the total amount received by ImmuPharma could exceed £6 million if the share price averages above 8.0 pence over 20 months.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings